IFI35 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 3 and 1 bp insertion in exon 3.
Images
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 3 and 1 bp insertion in exon 3
Alternative names
FLJ21753, IFP 35, IN35_HUMAN, Interferon-induced 35 kDa protein, OTTHUMP00000236626, OTTHUMP00000236627
Recommended products
IFI35 KO cell line available to order. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 3 and 1 bp insertion in exon 3.
Key facts
- Cell type
- A549
- Species or organism
- Human
- Tissue
- Lung
- Form
- Liquid
- Knockout validation
- Sanger Sequencing
- Mutation description
- Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon 3 and 1 bp insertion in exon 3
- Disease
- Carcinoma
- Concentration
Properties
- Gene name
- IFI35
- Gene editing type
- Knockout
- Gene editing method
- CRISPR technology
- Knockout validation
- Sanger Sequencing
Quality control
- STR analysis
- CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
Cell culture
- Biosafety level
- EU: 1 US: 1
- Adherent/suspension
- Adherent
- Gender
- Male
Handling procedures
- Initial handling guidelines
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.- Subculture guidelines
- All seeding densities should be based on cell counts gained by established methods.
- A guide seeding density of 2x104 cells/cm2 is recommended.
- Cells should be passaged when they have achieved 80-90% confluence.
- Do not allow the cell density to exceed 7x104 cells/cm2.
- Culture medium
- F-12K + 10% FBS
- Cryopreservation medium
- Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.
Storage
- Shipped at conditions
- Dry Ice
- Appropriate short-term storage conditions
- -196°C
- Appropriate long-term storage conditions
- -196°C
Notes
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.
Supplementary info
- This supplementary information is collated from multiple sources and compiled automatically.
- Activity summary
IFI35 also known as Interferon-induced 35 kDa protein plays a role mechanically in the regulation of immune responses. It has a molecular mass of approximately 35 kDa. This protein is expressed in various tissues with high levels found in the liver lungs and spleen. IFI35 interacts with numerous proteins particularly within the cytoplasm to execute its functions.
- Biological function summary
The protein modulates the innate immune system and interacts with other interferon-induced proteins. It forms a complex with NMI (N-Myc interactor) which stabilizes each other. Through these interactions IFI35 contributes to antiviral defense mechanisms and possibly acts in response to cellular stress.
- Pathways
IFI35 engages in the interferon signaling pathway and the Jak-STAT pathway. These pathways play critical roles in mediating immune responses to viral infections. IFI35 works together with related proteins like STAT1 and NMI within these pathways providing a framework for antiviral activity and influence on cell survival.
- Associated diseases and disorders
IFI35 has associations with viral infections and autoimmune diseases. Viral pathogenesis can see modulation by IFI35 particularly infections caused by the hepatitis C virus. Furthermore its interaction with NMI may also play a part in autoimmune disorders by influencing inflammatory responses. These links highlight IFI35's significant contributions to disease mechanisms and therapeutic potential in managing immune-related conditions.
Product promise
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
3 product images
Cell Culture - Human IFI35 knockout A549 cell line (ab267172)
Representative images of IFI35 knockout A549 cells, low and high confluency examples (top left and right respectively) and wild-type A549 cells, low and high confluency (bottom left and right respectively) showing typical adherent, epithelial-like morphology. Images were captured at 10X magnification using an EVOS M5000 microscope.
Sanger Sequencing - Human IFI35 knockout A549 cell line (ab267172)
Allele-1: 1 bp insertion in exon3
Sanger Sequencing - Human IFI35 knockout A549 cell line (ab267172)
Allele-2: 11 bp deletion in exon 3.
Downloads
Product protocols
- Visit the general protocols
- Visit troubleshooting
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com